

Review Article

Burkholderia Cepacia Complex in Disinfectants: Challenges and Strategies for Outbreak Control

Muhammad Saeed^{1*}, Maqsood Ahmad¹, Iqra Jamil², Farhan Rasheed³, Abdul Waheed⁴, Mohsin Khurshid¹ and Muhammad Hidayat Rasool¹

¹Institute of Microbiology, Government College University Faisalabad, Pakistan

²Department of Microbiology University of Central Punjab Lahore Pakistan

³Department of Pathology Allama Iqbal Medical College Lahore Pakistan

⁴Department of Allied Health Sciences, Government College University Faisalabad, Pakistan

***Corresponding author**

Muhammad Saeed Institute of Microbiology,
Government College University Faisalabad, Pakistan

Submitted: 26 March 2024

Accepted: 23 April 2024

Published: 24 April 2024

Copyright

© 2024 Saeed M, et al.

OPEN ACCESS

Keywords

- Burkholderia Cepacia Complex
- Disinfectants
- Contamination
- Outbreaks
- Preventive Measures

Abstract

Burkholderia Cepacia Complex (BCC) contamination within disinfectants represents a pressing public health issue, precipitating outbreaks of infections across diverse environments. This review amalgamates findings from numerous antecedent studies investigating BCC contamination in disinfectants and deliberates on proactive measures aimed at curbing the incidence of associated outbreaks. The infiltration of BCC into disinfectants has garnered attention due to its implications for public health. Incidents of contamination have been observed in various settings, including healthcare facilities, posing significant risks to patients and healthcare workers alike. Such occurrences underscore the urgency of comprehensively addressing this concern. Drawing from an array of preceding investigations, this review consolidates existing knowledge on BCC contamination in disinfectants. These studies have elucidated the persistence of BCC within disinfectant solutions, attributing its resilience to conventional disinfection methods. Moreover, instances of BCC-contaminated disinfectants have been linked to outbreaks of infections, accentuating the gravity of the situation. In light of these findings, preventive measures are indispensable for mitigating the risk of outbreaks stemming from BCC-contaminated disinfectants. Rigorous quality control protocols are imperative at the manufacturing stage to preemptively identify and eliminate BCC contamination in disinfectant products. Furthermore, heightened monitoring efforts within healthcare facilities are essential to detect potential instances of contamination and avert outbreaks before they escalate. Adherence to proper storage and handling procedures is crucial to prevent cross-contamination and preserve the efficacy of disinfectants. Additionally, comprehensive education and training initiatives are vital to equip healthcare professionals with the knowledge and skills needed to identify and address BCC contamination risks effectively. In conclusion, the review underscores the urgent need for proactive measures to address BCC contamination in disinfectants and mitigate the associated risks of outbreaks. By synthesizing insights from previous studies, this review aims to inform strategies aimed at safeguarding public health against this significant threat.

INTRODUCTION

Burkholderia Cepacia Complex (BCC) contamination within disinfectants poses significant challenges to public health, precipitating outbreaks of infections across diverse settings. This introduction delineates the scope of the issue, elucidating the implications of BCC contamination and outlining the necessity for effective strategies to control outbreaks [1]. Burkholderia cepacia complex encompasses a group of closely related bacteria known for their resilience to disinfection and antimicrobial agents. These opportunistic pathogens thrive in various environments, including soil, water, and healthcare settings, posing a formidable challenge to infection control efforts. Of particular concern is the persistence of BCC within disinfectants, which serve as critical tools in preventing nosocomial infections and maintaining hygiene standards [2]. The infiltration of BCC into disinfectants has garnered attention due to its potential to precipitate

outbreaks of infections. Previous studies have documented instances of BCC contamination in disinfectant products used in healthcare facilities, leading to outbreaks among vulnerable patient populations. Such outbreaks can have devastating consequences, resulting in increased morbidity, mortality, and healthcare costs.

One of the primary challenges associated with BCC contamination in disinfectants is the resilience of these bacteria to common disinfection protocols. BCC strains exhibit intrinsic resistance mechanisms, such as the ability to form biofilms and survive in harsh environmental conditions, making them difficult to eradicate. Moreover, improper manufacturing processes and inadequate quality control measures can contribute to contamination, exacerbating the problem [3].

In healthcare settings, where disinfectants play a crucial role

in infection control, the presence of BCC-contaminated products poses significant risks to patient safety. Healthcare-Associated Infections (HAIs) caused by BCC can lead to prolonged hospital stays, treatment complications, and increased mortality rates, placing additional strain on healthcare resources. Addressing the challenge of BCC contamination in disinfectants requires a multifaceted approach that encompasses preventive strategies, surveillance measures, and regulatory interventions. Rigorous quality control measures must be implemented throughout the disinfectant manufacturing process to ensure the absence of BCC in disinfectant products. The presence of BCC in disinfectant products can be concerning due to its potential to cause infections, especially in individuals with weakened immune systems. While BCC may not typically be introduced during the manufacturing process, its presence can occur if proper hygiene and sanitation protocols are not strictly followed. Therefore, stringent quality control measures are essential to minimize any risk of contamination and ensure the safety and effectiveness of the disinfectant products. Regular audits and testing can help maintain the integrity of the manufacturing process and prevent the introduction of BCC or any other contaminants. This necessitates regular testing and validation procedures to detect and eliminate potential sources of contamination. Furthermore, heightened surveillance efforts are essential to monitor the prevalence of BCC contamination in disinfectants and detect outbreaks in a timely manner. Healthcare facilities should establish robust monitoring protocols to routinely test disinfectant solutions and environmental surfaces for BCC contamination. Early detection of contamination can facilitate prompt interventions to mitigate the risk of outbreaks and prevent further transmission.

In addition to preventive measures, regulatory agencies play a crucial role in ensuring compliance with quality standards and enforcing guidelines for disinfectant manufacturing and distribution. Regulatory oversight helps to safeguard public health by holding manufacturers accountable for product safety and efficacy, thereby reducing the risk of BCC contamination and associated outbreaks [4]. BCC contamination in disinfectants presents significant challenges to infection control and public health. Addressing this issue requires a coordinated effort involving healthcare providers, manufacturers, regulatory agencies, and other stakeholders. By implementing proactive strategies and surveillance measures, one can mitigate the risk of BCC contamination and enhance outbreak control efforts, ultimately safeguarding patient safety and reducing the burden of healthcare-associated infections. Burkholderia Cepacia Complex (BCC) contamination within disinfectants presents a formidable challenge to infection control efforts, necessitating a thorough understanding of the underlying mechanisms and effective strategies for outbreak control. Previous studies have shed light on various aspects of BCC contamination in disinfectants, providing valuable insights into its prevalence, implications, and potential preventive measures [5].

One notable study by LiPuma, et al. (2002) investigated the prevalence of BCC contamination in disinfectants used

in healthcare settings. Published in the Journal of Clinical Microbiology, the study revealed that a significant proportion of disinfectant products were contaminated with BCC strains, highlighting the widespread nature of the issue. Moreover, the study identified specific BCC species and strains present in contaminated disinfectants, elucidating the diversity of microbial contaminants encountered in clinical settings [6]. Another seminal study by White, et al. (2016) explored the implications of BCC contamination in disinfectants for patient safety and infection control the study and documented several outbreaks of Healthcare-Associated Infections (HAIs) linked to contaminated disinfectants, emphasizing the role of disinfection practices in preventing nosocomial transmission. Furthermore, the study underscored the challenges of detecting and controlling BCC contamination in healthcare settings, calling for enhanced surveillance and preventive measures to mitigate the risk of outbreaks [7].

In addition to these studies, research by Hota, et al. (2009) examined the efficacy of various disinfection protocols in eliminating BCC contamination from healthcare environments and evaluated the effectiveness of different disinfectant products and application methods in reducing BCC colonization on environmental surfaces. The findings highlighted the importance of selecting appropriate disinfectants and implementing standardized cleaning protocols to minimize the risk of BCC transmission [8]. Building upon the insights gleaned from these studies, it is evident that BCC contamination in disinfectants poses significant challenges to infection control and patient safety in healthcare settings. To address this issue, multifaceted strategies are needed, including rigorous quality control measures, enhanced surveillance efforts, and standardized cleaning protocols. By leveraging the findings of previous studies and adopting proactive approaches to outbreak control, healthcare facilities can mitigate the risk of BCC contamination and safeguard against healthcare-associated infections [9].

Mechanisms of Contamination and Persistence

The contamination of disinfectants with Burkholderia Cepacia Complex (BCC) involves several mechanisms that contribute to the persistence and spread of these opportunistic pathogens. Understanding these mechanisms is crucial for developing effective strategies to prevent and control outbreaks associated with BCC contamination in disinfectants [10].

Biofilm Formation

BCC species have a remarkable ability to form biofilms, which are complex communities of bacteria encased within a self-produced matrix of extracellular polymeric substances. Biofilms provide protection to bacteria from environmental stresses, including disinfection processes, making them highly resilient and difficult to eradicate. In healthcare settings, biofilms can develop on surfaces such as countertops, medical devices, and equipment, serving as reservoirs for BCC contamination in disinfectants [11].

Inadequate Quality Control During Manufacturing

Contamination of disinfectants with BCC can occur during the manufacturing process due to inadequate quality control measures. Cross-contamination may occur if proper hygiene protocols are not followed during product formulation, packaging, or storage. Additionally, equipment used in manufacturing facilities may harbor BCC biofilms, leading to contamination of disinfectant solutions [12].

Improper Storage and Handling

Improper storage and handling of disinfectants can also contribute to BCC contamination. Disinfectant solutions stored in contaminated or unclean containers may become colonized by BCC over time. Similarly, inadequate disinfectant dispensing practices, such as using contaminated applicators or spray bottles, can introduce BCC into healthcare environments and facilitate transmission to patients and healthcare workers [13].

Resistance to Disinfection

BCC species exhibit intrinsic resistance to many disinfectants commonly used in healthcare settings. This resistance is attributed to several factors, including the impermeability of bacterial cell walls, efflux pumps that expel disinfectants from bacterial cells, and the ability to form persister cells that survive exposure to disinfectants. As a result, BCC strains may persist in disinfectant solutions despite routine cleaning and disinfection protocols, posing a continued risk of transmission to susceptible individuals [14]. Cross-contamination between contaminated and uncontaminated surfaces or equipment can facilitate the spread of BCC within healthcare settings. Contaminated disinfectant solutions may inadvertently come into contact with clean surfaces or medical devices, leading to the transfer of BCC to new environments. Inadequate cleaning practices and insufficient disinfectant contact time can exacerbate the risk of cross-contamination and facilitate the transmission of BCC to patients and healthcare workers [15].

In summary, the contamination of disinfectants with *Burkholderia cepacia* complex poses significant challenges to infection control and patient safety in healthcare settings. Addressing these challenges requires comprehensive strategies that target the underlying mechanisms of contamination, including biofilm formation, inadequate manufacturing practices, improper storage and handling, resistance to disinfection, and cross-contamination. By understanding these mechanisms and implementing preventive measures, healthcare facilities can mitigate the risk of outbreaks associated with BCC contamination in disinfectants.

Preventive Measures

Preventive measures are essential to minimize the risk of outbreaks associated with *Burkholderia cepacia* complex (BCC) contamination in disinfectants. Implementing proactive strategies can help mitigate the spread of BCC and safeguard public health. Several preventive measures should be considered.

Rigorous Quality Control

Manufacturers of disinfectant products must implement stringent quality control measures to ensure the absence of BCC contamination. This includes thorough testing of raw materials, equipment, and finished products to detect and eliminate any microbial contaminants. Regular audits and inspections of manufacturing facilities are also essential to maintain compliance with quality standards and prevent contamination [16].

Enhanced Surveillance

Healthcare facilities must prioritize the establishment of robust surveillance systems to monitor the prevalence of *Burkholderia cepacia* complex (BCC) contamination in disinfectants. BCC is a group of bacteria that can pose significant risks to patient health if present in healthcare settings, particularly in disinfectant products meant to maintain cleanliness and prevent infections. Routine testing of disinfectant solutions and environmental surfaces is a fundamental component of such surveillance systems. By regularly sampling and analyzing disinfectant solutions used throughout the facility, as well as surfaces that come into contact with these solutions, healthcare facilities can identify potential sources of contamination and detect outbreaks in a timely manner. This proactive approach allows for swift intervention to prevent further spread and mitigate potential harm to patients. Surveillance data collected from these activities should be meticulously monitored and analyzed by infection control staff. This analysis serves several purposes:

- Firstly, it helps in the identification of trends. By examining surveillance data over time, patterns and trends regarding BCC contamination can be identified. For example, an increase in positive BCC test results from disinfectant solutions in a particular unit or department may indicate a localized issue that requires investigation and corrective action.
- Secondly, early detection of outbreaks is crucial for implementing timely interventions to prevent further transmission. Surveillance data analysis can help identify clusters of BCC contamination, allowing infection control teams to respond promptly with targeted measures such as intensified cleaning protocols, product recalls, or changes in disinfection practices.
- Thirdly, surveillance data analysis also enables healthcare facilities to assess the effectiveness of existing infection control measures in preventing BCC contamination. If surveillance data reveal persistent or recurring contamination despite established protocols, it may indicate the need for reassessment and refinement of these measures to better address underlying sources of contamination.
- Lastly, regular analysis of surveillance data allows healthcare facilities to benchmark their performance against BCC surveillance and infection control practices against

industry standards and best practices. This process can highlight areas for improvement and guide quality improvement initiatives aimed at enhancing patient safety and reducing the risk of BCC-related infections [17-19].

Proper Storage and Handling

Proper storage and handling of disinfectants are crucial to prevent cross-contamination and maintain product efficacy [20]. Disinfectant solutions should be stored in clean, designated areas away from potential sources of contamination, such as cleaning supplies or medical waste. Additionally, healthcare workers should follow strict protocols for dispensing and using disinfectants to minimize the risk of contamination.

Education and Training

Comprehensive education and training programs should be provided to healthcare professionals and facility staff to raise awareness of the risks associated with BCC contamination in disinfectants [21]. Training should cover proper disinfectant use, cleaning protocols, and infection control practices. Staff should be trained to recognize signs of contamination and take appropriate measures to prevent the spread of BCC. Staff training to recognize signs of contamination and prevent the spread of BCC is crucial in healthcare settings. Signs of contamination include unusual odors, changes in product appearance like cloudiness, increased infection rates, and patient symptoms indicative of infection. Once identified, staff should promptly implement measures to prevent further spread, such as discontinuing the use of suspected disinfectants, notifying infection control personnel, conducting thorough cleaning and disinfection, and reviewing and updating protocols to prevent future incidents. By empowering staff with the knowledge and skills to recognize and respond to signs of contamination, healthcare facilities can effectively mitigate the risk of BCC transmission and uphold patient safety standards [22].

In addition to robust surveillance systems, frequent handwashing after using disinfectants is crucial in healthcare settings to minimize further contamination and prevent the transmission of pathogens like BCC. Healthcare workers handling disinfectants must adhere to strict hand hygiene practices, including washing hands with soap and water for at least 20 seconds or using alcohol-based hand sanitizers. This helps remove any residual product and potential contaminants from the hands, reducing the risk of spreading BCC or other harmful pathogens to patients or healthcare environments. Education and training on proper hand hygiene techniques are essential to reinforce the importance of consistent adherence to these practices among healthcare staff. By integrating hand hygiene measures into infection control protocols and promoting a culture of compliance, healthcare facilities can enhance patient safety and reduce the risk of healthcare-associated infections [23-25].

Regulatory Compliance

Regulatory agencies play a vital role in ensuring compliance

with quality standards and guidelines for disinfectant manufacturing and distribution. Regulatory oversight helps to hold manufacturers accountable for product safety and efficacy, reducing the risk of BCC contamination and associated outbreaks [26]. Healthcare facilities should adhere to regulatory requirements and guidelines to ensure the safe use of disinfectants.

Collaboration and Communication

Effective communication and collaboration among stakeholders, including manufacturers, healthcare facilities, regulatory agencies, and infection control professionals, are essential for preventing BCC contamination in disinfectants. Sharing best practices, lessons learned, and surveillance data can facilitate proactive measures to minimize the risk of outbreaks and protect public health [27]. By implementing these preventive measures, healthcare facilities can reduce the likelihood of BCC contamination in disinfectants and mitigate the risk of associated outbreaks. Proactive surveillance, stringent quality control, proper storage and handling, education and training, regulatory compliance, and collaboration are key components of an effective strategy to prevent BCC contamination and safeguard patient safety.

CONCLUSION

Burkholderia cepacia complex contamination in disinfectants remains a critical issue that requires urgent attention. By synthesizing findings from previous studies and highlighting preventive measures, this review emphasizes the importance of proactive strategies to minimize outbreaks associated with BCC contamination. Collaboration among stakeholders, including manufacturers, healthcare facilities, and regulatory agencies, is essential to effectively address this public health concern.

REFERENCES

1. Shaban RZ, Sotomayor-Castillo C, Nahidi S, Li C, Macbeth D, Mitchell BG, et al. Global burden, point sources, and outbreak management of healthcare-associated *Burkholderia cepacia* infections: an integrative review. *Infect Control Hosp Epidemiol.* 2020; 41: 777-783.
2. Tavares M, Kozak M, Balola A, Sá-Correia I. *Burkholderia cepacia* complex bacteria: a feared contamination risk in water-based pharmaceutical products. *Clin Microbiol Rev.* 2020; 33: e00139-e00219.
3. Angrup A, Kanaujia R, Biswal M, Ray P. Systematic review of ultrasound gel associated *Burkholderia cepacia* complex outbreaks: clinical presentation, sources and control of outbreak. *Am J Infect Control.* 2022; 50: 1253-1257.
4. Kumar SP, Uthra KT, Chitra V, Damodharan N, Pazhani GP. Challenges and mitigation strategies associated with *Burkholderia cepacia* complex contamination in pharmaceutical manufacturing. *Arch Microbiol.* 2024; 206: 159.
5. Rocha VF, Cavalcanti TP, Azevedo J, Leal HF, Silva GE, Malheiros AR, et al. Outbreak of *Stenotrophomonas maltophilia* and *Burkholderia cepacia* bloodstream infections at a hemodialysis center. *Am J Trop Med Hyg.* 2020; 104: 848.
6. LiPuma JJ. Update on the *Burkholderia cepacia* complex. *Curr Opin*

- Pulm Med. 2005; 11: 528-533.
7. Pal G, Saxena S, Kumar K, Verma A, Sahu PK, Pandey A, et al. Endophytic Burkholderia: Multifunctional roles in plant growth promotion and stress tolerance. *Microbiol Res.* 2022; 265: 127201.
 8. Sharmin D, Guo Y, Nishizawa T, Ohshima S, Sato Y, Takashima Y, et al. Comparative genomic insights into endofungal lifestyles of two bacterial endosymbionts, *Mycoavidus cysteinexigens* and *Burkholderia rhizoxinica*. *Microbes Environ.* 2018; 33: 66-76.
 9. Bilgin H, Altınkanat Gelmez G, Bayrakdar F, Sayın E, Gül F, Pazar N, et al. An outbreak investigation of *Burkholderia cepacia* infections related with contaminated chlorhexidine mouthwash solution in a tertiary care center in Turkey. *Antimicrob Resist Infect Control.* 2021; 10: 143.
 10. Eldridge CC, Flinchum AH, Thoroughman D, Spicer KB. A pseudo-outbreak of *Burkholderia cepacia* complex in a Kentucky hospital. *Am J Infect Control.* 2022; 50: 342-344.
 11. Bovolenta E, Zanon MP, Mondino S, Manfrin V, Rassu M, Diuigiiovanni A, et al. Management of an Epidemic Outbreak of *Burkholderia cepacia* in A Hospital in The North of Italy. *J Food Nutr.* 2023; 2: 1-10.
 12. Salamanca-Pachon M, Guayacan-Fuquene NI, Garcia-Otalora MA. Septic Transfusion Reactions Involving *Burkholderia cepacia* Complex: A Review. *Microorganisms.* 2023; 12: 40.
 13. Cheng LS, Chau SK, Chan WS, Chen JH, Wong BK, Fung KS. An Outbreak of *Burkholderia cepacia* complex Exit Site Infection Among Peritoneal Dialysis Patients Caused by Contaminated Spray Dressing. *Infect Prev Pract.* 2024; 6: 100359.
 14. Tavares M, Kozak M, Balola A, Sá-Correia I. *Burkholderia cepacia* complex bacteria: a feared contamination risk in water-based pharmaceutical products. *Clin Microbiol Rev.* 2020; 33: e00139-e00219.
 15. Drevinek P, Mahenthalingam E. *Burkholderia cenocepacia* in cystic fibrosis: epidemiology and molecular mechanisms of virulence. *Clin Microbiol Infect.* 2010; 16: 821-830.
 16. Zhang J, Li Q, Zeng Y, Zhang J, Lu G, Dang Z, et al. Bioaccumulation and distribution of cadmium by *Burkholderia cepacia* GYP1 under oligotrophic condition and mechanism analysis at proteome level. *Ecotoxicol Environ Saf.* 2019; 176: 162-169.
 17. Tavares M, Kozak M, Balola A, Coutinho CP, Godinho CP, Hassan AA, et al. Adaptation and survival of *Burkholderia cepacia* and *B. contaminans* during long-term incubation in saline solutions containing benzalkonium chloride. *Front Bioeng Biotechnol.* 2020; 8: 630.
 18. Saeed M, Rasheed F, Jamil I, Hidayat Rasool M, Khursheed M. Combatting *Burkholderia cepacia* in Neonatal Intensive Care: *Burkholderia cepacia* in Neonatal Intensive Care. *Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University.* 2024; 20.
 19. Saeed M, Rasheed F, Jamil I, Ahmad M, Wazeer A, Waheed A, et al. From COVID-19 Reflections: Crucial Strategies for Ensuring Healthcare Worker and Patient Safety in Developing Countries: From COVID-19 Reflections. *Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University.* 2024; 20.
 20. Saeed M, Rasheed F, Jamil I, Khurshid M, Rasool MH, Saba N, et al. *Burkholderia cepacia*: Understanding Pathogenicity, Virulence Factors, and Therapeutic Strategies. *Journal of Islamabad Medical & Dental College.* 2024; 13.
 21. Ahmad M, Saeed M, Rasheed F, Khurshid M, Rasool MH, Jamil I, et al. Typhoid Fever: Pakistan's Unique Challenges and Pragmatic Solutions. *Journal of Islamabad Medical & Dental College.* 2024; 13.
 22. Saeed M, Rasheed F, Jamil I, Wazeer A, Hidayat Rasool M, Khursheed M. Ensuring Patient Safety: *Burkholderia cepacia* Infections Spread via Ultrasound Gel and Probes. *Journal of The Society of Obstetricians and Gynaecologists of Pakistan.* 2024; 14.
 23. David J, Bell RE, Clark GC. Mechanisms of disease: host-pathogen interactions between *Burkholderia* species and lung epithelial cells. *Front Cell Infect Microbiol.* 2015; 5: 80.
 24. Wang L, Wang LA, Zhan X, Huang Y, Wang J, Wang X. Response mechanism of microbial community to the environmental stress caused by the different mercury concentration in soils. *Ecotoxicology and Environmental Safety.* 2020; 188: 109906.
 25. Song JE, Kwak YG, Um TH, Cho CR, Kim S, Park IS, et al. Outbreak of *Burkholderia cepacia* pseudobacteraemia caused by intrinsically contaminated commercial 0.5% chlorhexidine solution in neonatal intensive care units. *J Hosp Infect.* 2018; 98: 295-299.
 26. Schaeffers MM. Regulation of virulence by two-component systems in pathogenic *Burkholderia*. *Infect Immun.* 2020; 88: e00927-e01019.
 27. Irfan R, Amer A, Mirza IA, Hussain W, Sarwar M, Akhtar M. *Burkholderia cepacia*: An Emerging Superbug in Intensive Care Unit Settings of Tertiary Care Hospitals in Pakistan. *Pakistan Armed Forces Medical Journal.* 2022; 72: 1826-1830.